Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

B.F. Ascher Halts Supplement/OTC Combo Sales Following FDA Warnings

This article was originally published in The Tan Sheet

Executive Summary

B.F. Ascher has discontinued the sale of its Melagesic PM dietary supplement/OTC combination in response to FDA's decision the product is an unapproved new drug, according to the agency
Advertisement

Related Content

FDA Warning Letter Review Suggests Aggressive Action Needed, Troy Says
FDA Warning Letter Review Suggests Aggressive Action Needed, Troy Says
FDA Warning Letter Review Suggests Aggressive Action Needed, Troy Says
Omni Nutraceuticals
Omni Nutraceuticals
Omni Nutraceuticals
Supplement/OTC Combos Have Precedents In Other Categories, Firms State
OTC/Dietary Supplement Combination Guidance “Unlikely” – FDA
OTC/Dietary Supplement Combination Guidance “Unlikely” – FDA

Topics

Advertisement
UsernamePublicRestriction

Register

PS093622

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel